Development of a Unique Rapid Test to Detect Antibodies Directed Against an Extended RBD of SARS-CoV-2 Spike Protein

被引：2

作者：

Brosi, Larissa ^{[1
,2
]}

Kuebler, Eric ^{[1
]}

Weston, Anna ^{[1
]}

Romann, Patrick ^{[1
]}

Panikulam, Sherin ^{[1
]}

Dirscherl, Lorin ^{[2
]}

Gerspach, Michael ^{[2
]}

Giegelmann, Cedric ^{[2
]}

Dolce, Daniele

Ueberschlag, Marie-Eve ^{[2
]}

Melone, Anna ^{[2
]}

Bantleon, Frank, I ^{[2
]}

Villiger, Thomas K. ^{[1
]}

Gerhold, Christian-B ^{[2
]}

机构：

[1] FHNW, Sch Life Sci, Hofackerstr 30, CH-4132 Muttenz, Switzerland

[2] BUHLMANN Labs AG, Baselstr 55, CH-4124 Schonenbuch, Switzerland

来源：

CHIMIA | 2021年 / 75卷 / 05期

关键词：

Antibodies; Lateral Flow Assay; Point-of-Care; RBD; SARS-CoV-2; COVID-19;

D O I：

10.2533/chimia.2021.446

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

Serological testing for antibodies directed against SARS-CoV-2 in patients may serve as a diagnostic tool to verify a previous infection and as surrogate for an elicited humoral immune response, ideally conferring immunity after infection or vaccination. Here, we present the recombinant expression of an extended receptor binding domain (RBD) of the SARS-CoV-2 Spike protein used as capture antigen in a unique rapid immunoassay to detect the presence of RBD binding antibodies with high sensitivity and specificity. As currently available vaccines focus on the Spike RBD as target, the developed test can also be used to monitor a successful immune response after vaccination with an RBD based vaccine.

引用

页码：446 / 452

页数：7

共 16 条

[1] The effect of the D614G substitution on the structure of the spike glycoprotein of SARS-CoV-2
Benton, Donald J.
Wrobel, Antoni G.
Roustan, Chloe
Borg, Annabel
Xu, Pengqi
Martin, Stephen R.
Rosenthal, Peter B.
Skehel, John J.
Gamblin, Steven J.
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2021, 118 (09)
[2] Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study
Challen, Robert
Brooks-Pollock, Ellen
Read, Jonathan M.
Dyson, Louise
Tsaneva-Atanasova, Krasimira
Danon, Leon
[J]. BMJ-BRITISH MEDICAL JOURNAL, 2021, 372
[3] Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19
Chen, Wen-Hsiang
Hotez, Peter J.
Bottazzi, Maria Elena
[J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2020, 16 (06) : 1239 - 1242
[4] Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: Implication for vaccine design
He, Yuxian
Li, Jingjing
Heck, Susanne
Lustigman, Sara
Jiang, Shibo
[J]. JOURNAL OF VIROLOGY, 2006, 80 (12) : 5757 - 5767
[5] Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies
He, YX
Lu, H
Siddiqui, P
Zhou, YS
Jiang, SB
[J]. JOURNAL OF IMMUNOLOGY, 2005, 174 (08) : 4908 - 4915
[6] SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Hoffmann, Markus
Kleine-Weber, Hannah
Schroeder, Simon
Krueger, Nadine
Herrler, Tanja
Erichsen, Sandra
Schiergens, Tobias S.
Herrler, Georg
Wu, Nai-Huei
Nitsche, Andreas
Mueller, Marcel A.
Drosten, Christian
Poehlmann, Stefan
[J]. CELL, 2020, 181 (02) : 271 - +
[7] Huo JD, 2020, NAT STRUCT MOL BIOL, V27, P846, DOI [10.1038/s41594-020-0469-6, 10.1038/s41594-020-00527-9]
[8] Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients
Li, Yang
Lai, Dan-yun
Zhang, Hai-nan
Jiang, He-wei
Tian, Xiaolong
Ma, Ming-liang
Qi, Huan
Meng, Qing-feng
Guo, Shu-juan
Wu, Yanling
Wang, Wei
Yang, Xiao
Shi, Da-wei
Dai, Jun-biao
Ying, Tianlei
Zhou, Jie
Tao, Sheng-ce
[J]. CELLULAR & MOLECULAR IMMUNOLOGY, 2020, 17 (10) : 1095 - 1097
[9] COVID-19: consider cytokine storm syndromes and immunosuppression
Mehta, Puja
McAuley, Daniel F.
Brown, Michael
Sanchez, Emilie
Tattersall, Rachel S.
Manson, Jessica J.
[J]. LANCET, 2020, 395 (10229) : 1033 - 1034
[10] Validation of a commercially available SARS-CoV-2 serological immunoassay
Meyer, B.
Torriani, G.
Yerly, S.
Mazza, L.
Calame, A.
Arm-Vernez, I
Zimmer, G.
Agoritsas, T.
Stirnemann, J.
Spechbach, H.
Guessous, I
Stringhini, S.
Pugin, J.
Roux-Lombard, P.
Fontao, L.
Siegrist, C-A
Eckerle, I
Vuilleumier, N.
Kaiser, L.
[J]. CLINICAL MICROBIOLOGY AND INFECTION, 2020, 26 (10) : 1386 - 1394

← 1 2 →